热门资讯> 正文
周六报道称，Alumis的ESK-001在II期银屑病研究中在第52周表现出持续的PAS 90和PAS 100反应
2025-03-10 15:43
- ESK-001 is a highly selective, next-generation oral tyrosine kinase 2 (TYK2) inhibitor currently under development in moderate-to-severe plaque psoriasis and systemic lupus
- Phase 2 OLE data of ESK-001 at 40 mg BID demonstrated sustained or increasing clinical responses through week 52 on PASI 90, PASI 100, and sPGA 0
- ESK-001 was generally well-tolerated at one year, with no new safety findings
- Data further support ESK-001's potential to offer a highly differentiated and best-in-class treatment option for people with moderate-to-severe plaque psoriasis
- Phase 3 ONWARD program ongoing with topline data expected in Q1 2026
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
